

September 19, 2025
PDRadiopharma Inc.

Bridgea DISPENSER Now Equipped with Liquid Collection Function — Enhancing Operational Efficiency and Safety in Radiopharmaceutical Preparation

**This release is an English translation of “「放射性医薬品の投与支援装置「Bridgea DISPENSER」に“集液機能”を追加 —作業効率と安全性を向上”, with a priority given to Japanese for content and interpretation. The indication is specifically for Japan only and not for other countries.*

TOKYO, JAPAN – September 19, 2025 – PDRadiopharma Inc. (President: Masato Murakami; Headquarters: Chuo-ku, Tokyo, Japan) today announced the addition of a new feature—the Liquid Collection and Dispensing Function for Radiopharmaceuticals—to its radiopharmaceutical administration support device, **Bridgea DISPENSER**^{※1}.

This new feature was developed to reduce the workload and radiation exposure for healthcare professionals when preparing doses from multiple vials—particularly in response to the newly approved indication for neuroblastoma for **Raiatt MIBG-I 131 Injection**^{※2} (approved on September 19, 2025).

New Features 1: Automated Liquid Adjustment for Improved Efficiency and Accuracy

- Using Bridgea DISPENSER, healthcare professionals can now extract liquid from multiple vials and consolidate the desired volume into one or more vials or syringes. This automation replaces manual preparation, improving both workflow efficiency and dosing precision.

New Features 2: Enhanced Safety During Administration

- By simplifying the complex preparation process and reducing radiation exposure, Bridgea DISPENSER contributes to safer handling and administration of radiopharmaceuticals.

Beyond the supply of radiopharmaceuticals, we are committed to solving information management challenges by integrating data and digital technologies with medical DX solutions. We will continue to contribute to the advancement of safe and efficient radiopharmaceutical medicine while delivering higher-quality services.

※1 **Bridgea DISPENSER** is a device that extracts radiopharmaceutical solution from vials stored in dedicated containers—primarily supplied by pharmaceutical manufacturers—and adjusts the volume according to specific dosage requirements.

※2 **Raiatt MIBG-I 131 Injection** is a pharmaceutical product in which radioactive iodine (¹³¹I) is attached to 3-iodobenzylguanidine (MIBG), a substance similar to the adrenal medullary hormone norepinephrine. It is specifically taken up by tumors through a mechanism similar to that of norepinephrine, and the β-rays emitted from the ¹³¹I cause damage to the tumor cells, thereby exerting therapeutic effects.

About PDRadiopharma

PDRadiopharma, a wholly-owned subsidiary of PeptiDream from 2022, has been providing high-quality radiopharmaceuticals through the research and development, manufacturing, regulatory and sales as a forerunner in the field of radiopharmaceuticals, since it started its business in 1968. Currently PDRadiopharma offers 22 radiodiagnostic products (spanning both SPECT and PET products) and 8 radiotherapeutic products (3 product categories) in Japan. Additionally, PDRadiopharma and PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the Japan and global markets. For more information about PDRadiopharma, please visit <https://www.pdradiopharma.com/>

Inquiries:

PDRadiopharma Inc.

Contact: Akiko Murakami, General Affairs

Email: s-info-hq@pdradiopharma.com